Introductory Comments About the Special Series of Thrombotic Microangiopathy

Overview

Journal Ann Blood

Publisher AME Publishing Company

Date 2024 Jul 25

PMID 39049904

Authors

X Long Zheng

Affiliations

Soon will be listed here.

References

Asmis L, Serra A, Krafft A, Licht A, Leisinger E, Henschkowski-Serra J . Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2022; 387(25):2356-2361. DOI: 10.1056/NEJMoa2211113. View

Afshar-Kharghan V . Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):217-225. PMC: 6142509. DOI: 10.1182/asheducation-2016.1.217. View

Camilleri R, Scully M, Thomas M, Mackie I, Liesner R, Chen W . A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost. 2012; 10(9):1792-801. DOI: 10.1111/j.1538-7836.2012.04852.x. View

Casina V, Hu W, Mao J, Lu R, Hanby H, Pickens B . High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome. Proc Natl Acad Sci U S A. 2015; 112(31):9620-5. PMC: 4534270. DOI: 10.1073/pnas.1512561112. View

Halkidis K, Meng C, Liu S, Mayne L, Siegel D, Zheng X . Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura. Blood. 2023; 141(24):2993-3005. PMC: 10315623. DOI: 10.1182/blood.2022019252. View

Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T . Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood. 2019; 133(15):1644-1651. DOI: 10.1182/blood-2018-11-884700. View

Joly B, Boisseau P, Roose E, Stepanian A, Biebuyck N, Hogan J . ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome. Thromb Haemost. 2018; 118(11):1902-1917. DOI: 10.1055/s-0038-1673686. View

Underwood M, Alwan F, Thomas M, Scully M, Crawley J . Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2023; 21(6):1544-1552. DOI: 10.1016/j.jtha.2023.02.011. View

Zheng L, Zheng X . How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?. Ann Blood. 2023; 8. PMC: 10187608. DOI: 10.21037/aob-21-87. View

10.

Zheng X, Chung D, Takayama T, Majerus E, Sadler J, Fujikawa K . Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276(44):41059-63. DOI: 10.1074/jbc.C100515200. View

11.

Moake J, Rudy C, Troll J, Weinstein M, Colannino N, Azocar J . Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307(23):1432-5. DOI: 10.1056/NEJM198212023072306. View

12.

Tsai H, Lian E . Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-94. PMC: 3159001. DOI: 10.1056/NEJM199811263392203. View

13.

Halkidis K, Lammle B, Zheng X . The history of thrombotic thrombocytopenic purpura research: a narrative review. Ann Blood. 2024; 9. PMC: 11268837. DOI: 10.21037/aob-23-46. View

14.

Stubbs M, Kendall G, Scully M . Recombinant ADAMTS13 in Severe Neonatal Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2022; 387(25):2391-2392. DOI: 10.1056/NEJMc2210781. View

15.

Keir L, Marks S, Kim J . Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther. 2012; 6:195-208. PMC: 3414372. DOI: 10.2147/DDDT.S25757. View

16.

Zheng X . The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost. 2021; 19(8):1864-1871. PMC: 8324529. DOI: 10.1111/jth.15406. View

17.

Scully M, Knobl P, Kentouche K, Rice L, Windyga J, Schneppenheim R . Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017; 130(19):2055-2063. PMC: 5680611. DOI: 10.1182/blood-2017-06-788026. View

18.

Shelat S, Smith P, Ai J, Zheng X . Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006; 4(8):1707-17. PMC: 2577225. DOI: 10.1111/j.1538-7836.2006.02025.x. View

19.

Gerritsen H, Robles R, Lammle B, Furlan M . Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98(6):1654-61. DOI: 10.1182/blood.v98.6.1654. View

20.

Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B . Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997; 89(9):3097-103. View